66 results about "Fusidic acid" patented technology

A mixed liposome pharmaceutical formulation with multilamellar vesicles, comprises a proteinic pharmaceutical agent, water, an alkali metal lauryl sulphate in a concentration of from 1 to 10 wt. / wt. %, at least one membrane-mimetic amphiphile and at least one phospholipid. The membrane-mimetic amphiphile is hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, lauramidopropyl betain, lauramide monoisopropanolamide, sodium cocoamphopropionate, bishydroxypropyl dihydroxypropyl stearammonium chloride, polyoxyethylene dihydroxypropyl stearammonium chloride, dioctadecyldimethylammonium chloride, sulphosuccinates, stearamide DEA, gamma-linoleic acid, borage oil, evening of primrose oil, monoolein, sodium tauro dihydro fusidate, fusidic acid, alkali metal isostearyl lactylates, alkaline earth metal isostearyl lactylates, panthenyl triacetate, cocamidopropyl phosphatidyl PG-diammonium chloride, stearamidopropyl phosphatidyl PG-diammonium chloride, borage amidopropyl phosphatidyl PG-diammonium chloride, borage amidopropyl phosphatidylcholine, polysiloxy pyrrolidone linoleyl phospholipid, trihydroxy-oxo-cholanylglycine and alkali metal salts thereof, and octylphenoxypolythoxyethanol, polydecanol X-lauryl ether, polydecanol X-oleyl ether, wherein X is from 9 to 20, or combinations thereof. The phospholipid is phospolipid GLA, phosphatidyl serine, phosphatidylethanolamine, inositolphosphatides, dioleoylphosphatidylethanolamine, sphingomyelin, ceramides, cephalin, triolein, lecithin, saturated lecithin and lysolecithin, or a combination thereof. The amount of each membrane mimetic amphiphile and phospholipid is present 1 to 10 wt. / wt. % of the total formulation, and the total concentration of membrane mimetic amphiphiles and phospholipids is less than 50 wt. / wt. % of the formulation.

The invention relates to a method for detecting content of orange fusidic acid in fermentation products, which comprises following steps of: 1. sample color value measuring step; 2. sample processing before detecting, includes: (1) extracting orange fusidic acid from sample: weighing up sample; adding methyl alcohol extract; mixing with ultrasonic and then centrifugation extracting; depression compressing in ambient temperature; (2) making absorbing chromatography column for crude separation step includes: column packing with neutral absorbing resin washed with methyl alcohol; (3) crude separation of the orange fusidic acid in the sample; 3. identifying conditions of liquid chromatography; 4. analyzing chromatography; 5. making standard solution and standard curve; 6. calculating results.

Methods for the treatment of bacterial infections in the respiratory system of a subject, such as the lungs of a subject, using fusidic acid alone or in combination with a second bacterial agent such as tobramycin, amikacin, fosfomycin or levofloxacin are described.

The invention discloses a medical composite alginate dressing containing antibacterial drugs and a preparation method thereof. In parts by weight, the medical composite alginate dressing comprises the following components: 50-99.9 parts of alginate and 0.05-10 parts of antibacterial drugs, The antibacterial drug is selected from gentamicin or its salt, neomycin or its salt, amikacin or its salt, fusidic acid or its salt, kanamycin or its salt, polycresol , mupirocin, sulfamethonium or its salt and clindamycin or its salt at least one. The medical composite alginate dressing of the present invention has strong ability to absorb exudate, has good water vapor transmission rate, can be biodegraded and has good biocompatibility, does not adhere to the wound and can quickly form gel after absorbing wound exudate , has strong moisturizing properties, can effectively promote wound healing, shorten wound repair time, can effectively prevent or treat sensitive bacterial infections, and can be widely used in acute and chronic wounds with exudate.

Described are solid pharmaceutical compositions of fusidic acid, and pharmaceutically acceptable salts thereof, dosage units of the pharmaceutical compositions, and packages for pharmaceutical compositions of fusidic acid, and pharmaceutically acceptable salts thereof, which increase stability against the degradation of the fusidic acid, and pharmaceutically acceptable salts thereof. Also described are uses of the pharmaceutical compositions and dosage units in treating diseases.

Novel dosing regimens for the treatment and prevention of bacterial infections using fusidic acid are described. The use of a high loading dose of fusidic acid, followed by moderate maintenance doses of the drug, have been found to prevent development of drug-resistant strains of bacteria, to increase the effective spectrum of the drug, and to avoid nausea and vomiting associated with a prolonged course of therapy of high amounts of the drug.

The present Invention relates to novel fusidic acid derivatives of general formula [I] wherein X represents halogen, trifluoromethyl, cyano, azido, alkyl, alkenyl or aryl, wherein. said alkyl, alkenyl or aryl are optionally substituted by one or more, same or. different substituents selected from the group consisting of alkyl, alkenyl, aryl, alkoxy, nitro, alkylthio, halogen, azido, trifluoromethyl and cyano; Y and Z both' represent hydrogen, or together with the C-17 / C-20 bond form a double bond between C-17 and C-20, or together are methylene and form a cyclopropane ring in combination with C-17 and C-20; A represents a bond,. O, S or S(O); B represents C1-6 alkyl, C2-6 alkenyl, CI-6 acyl, C3-7 cycloalkylcarbonyl or benzoyl, all of which are optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxy, alkoxy, aryl, heteroaryl and azido, or, if A represents a bond, B may also represent hydrogen; Q1 and 'Q2 independently represent. -CH2-, -C(O)-, -(CHOR)-, -(CHOR)-, -(CHSH)-, - (NH)<->, -(CHNH2)- or -(CHW)-., wherein R represents CI-6alkyl and W represents halogen, cyano, azido or trifluoromethyi; Q3 represents -CH2-, -C(O)- or -CHOH-; G represents hydrogen, OH or O-CO-CH3; two bonds in the pentacyclic ring being depicted with full and dotted lines to indicate that either of the two bonds may be a double bond, in which case Y is absent and Z represents hydrogen; the bond between C-1 and C-2 being either a single or a double bond; and pharmaceutically acceptable salts and easily hydrolysable esters thereof, to pharmaceutical compositions comprising said derivatives, as well as to their use in therapy.

Aiming at the defects that a fusidic acid preparation is easy to oxidatively degrade and hydrolyze, an inventor proposes to avoid oxidation and hydrolysis reaction by a mode of adding an antioxidant into a preparation system and hydrolyzing a stabilizer; the problem of dissolution of fusidic acid is successfully solved by selecting particle sizes of crude drugs and dissolving, the fusidic acid can exist in cream in a molecular state, and stability and curative effect of a cream preparation are improved.

Disclosed is an acid addition salt of donepezil, wherein acid counterion is selected from the group consisting of pamoic acid, cypionic acid, camphor sulfonic acid, enanthic acid, fusidic acid, gluceptic acid, gluconic acid, lactobionic acid, lauric acid, valeric acid, Dibenzoyl-D-Tartaric acid and terephthalic acid. Disclosed is a process for the preparation and pharmaceutical composition comprising the same. More specifically, disclosed is concerned with the pamoate acid addition salts of donepezil. Disclosed also is long acting formulation comprising the acid addition salt of donepezil and process for the preparation thereof.

The present invention relates to topical pharmaceutical compositions comprising fusidic acid and a corticosteroid. More particularly, the present invention relates to topical pharmaceutical compositions comprising fusidic acid and mometasone or halobetasol or their esters, processes for preparing the same, and the use of such compositions for prevention and treatment of dermal infections.

The present invention relates to processes for the crystallisation and for the preparation and isolation of a novel crystalline form of fusidic acid, to the use of said processes in the manufacture of pharmaceutical formulation or medicament, and to the use of said crystalline fusidic acid form for the treatment of bacterial infections.

The invention discloses a making method of jinggang fusidic acid powder, which comprises the following steps: filtering the ferment liquid of jinggang fusidic acid; obtaining the filtrate; removing impurity through strongly basic anion ion resin; using strongly acid cation to adsorb the jinggang fusidic acid; washing the jinggang fusidic acid through deionized water after adsorbing; eluting through 0. 5-1. 5N ammonia; collecting the eluent with jinggang fusidic acid A; decompressing and evaporating the eluent of jinggang fusidic acid A to remove ammonia; obtaining the solution of jinggang fusidic acid; adjusting the density of jinggang fusidic acid solution at 100-500mg / ml; pumping the solution into spraying drier to spray and dry; obtaining the product. The invention has stronger hygroscopic problem, which has good color and luster, solubility, hygroscopicity resistance and instant property.

The invention discloses a fermentation production method of fusidic acid, which belongs to the technical field of fermentation engineering. The method comprises the stages of seed culture, preparation before inoculation, inoculation, multi-stage dissolved oxygen control and batch material supplementing fermentation. Fucidin can be produced through multi-stage fermentation, so the valence of the secondary metabolite of fusidic acid of the strain is greatly improved. The invention has the advantages of simple operation and low cost, and realizes the biological method production of antibiotics of the fusidic acid, in addition, target products of the fusidic acid obtained through the fermentation have high valence, and the invention is favorable for industrial production.

The invention relates to the field of organic synthesis and medicine chemicals and in particular relates to fusidic acid derivatives of novel structures. The invention further discloses a preparationmethod of the derivatives, medicinal compositions with the derivatives, and application of the derivatives in bacterium resistance. Pharmacological testing shows that the fusidic acid derivatives provided by the invention have good antibacterial function, and can be used for preparing anti-infection medicines. Compared with fusidic acid, the fusidic acid derivatives have a staphylococcus aureus inhibition rate of 83.65%; the derivatives provided by the invention have good activity upon staphylococcus aureus, the antibacterial inhibition rate is increased to 90.8% from 83.65%, and remarkable activity improvement is achieved; meanwhile, HC (Hydrocarbon Compound) evaluation results of the derivatives show that the derivatives have no cytotoxicity.

The invention provides a method for extracting and separating fusidic acid. The method comprises the following steps: (1) extracting and separating fusidic acid concentrated solution by ultrafiltration; and (2) preparing fusidic acid crystal by the fusidic acid concentrated solution, wherein, a qualified fusidic acid product can be prepared by the fusidic acid concentrated solution through solvent extraction, decoloring, crystal separation, drying, crushing, screening, inspecting, finished product package and other production steps. The method has the advantages of short production process flow, high product purity, high yield, high automation degree, small environmental pollution, low production cost and the like, and is particularly suitable for industrial large-scale production of the fusidic acid.

The invention discloses a new uses of helvolicacid sterides in making drugs of antibiotic-resistant microbes, including helvolicacid, fusidic acid and its salt and salt hydrates acceptable in pharmacology, compound of ester or prodrug with single or multi-antibiotic, applying to preparation of drugs of antibiotic-resistant microbes.

The invention belongs to the field of microbial fermentation engineering, and particularly relates to a culture medium for producing fusidic acid by a fermentation method. The culture medium comprises a seed culture medium and a fermentation culture medium. When cheap cottonseed cake powder and soybean meal are utilized by fusidium coccineum to perform organic nitrogen source fermentation, the fusidic acid fermentation can be stably performed, so the yield is improved, the conversion rate of a final product reaches about 50 percent, and the cost of the culture medium is controlled.

The invention discloses a medicine for reducing the side effect of fusidic acid in clinical use, and belongs to the technical field of medicines for external use. The medicine for reducing the side effect of the fusidic acid in clinical use comprises a component A and a component B, wherein the component A is fusidic acid cream, and the component B is a Chinese herb extract. The medicine disclosed by the invention is obtained by fully mixing and uniformly stirring the component A and the component B according to a weight ratio of 1:2. A clinical experiment shows that the medicine has an outstanding treating effect on acne vulgaris and can reduce the side effect of the fusidic acid in clinical use.

The present invention relates to novel 17,20-dihydrofusilic acid derivatives (Ia) for use in pharmaceutical compositions for the treatment of infections, in particular topical compositions for the treatment of skin infections or eye infections.

The invention provides a novel fusidic acid derivative shown in the following formula, wherein R represents basic amino acid residues such as lysines and arginines and can be of L-configuration, D-configuration or DL-configuration. The novel fusidic acid derivative shown in the formula can be used for preparing medicines for treating fusidic acid sensitized bacterial inflection.

The invention discloses a fusidic acid high-yield strain as well as a breeding method and application thereof. The name of the fusidic acid high-yield strain is fusidium coccineum NJWW-0520, preservedin the Center for General Microbiology of the China Microbial Culture Collection Management Committee on March 21, 2018 with the preservation number of CGMCC No.15473. The fusidic acid high-yield strain is bred by stress-oriented domestication of a fusidic acid producing strain by continuously using DMSO (dimethyl sulfoxide) for a long time. The yield of fusidic acid produced by fermentation of the domesticated strain is as high as 4,932 [mg]g / ml, which is 53.88 percent higher than that of the original strain (3,205 [mg]g / ml), and the fusidic acid high-yield strain is fully applied in efficient preparation of the fusidic acid by an actual biological method.

The present invention relates to processes for the crystallisation and for the preparation and isolation of a novel crystalline form of fusidic acid, to the use of said processes in the manufacture of pharmaceutical formulation or medicament, and to the use of said crystalline fusidic acid form for the treatment of bacterial infections.

The invention relates to a pharmaceutical composition of fusidic acid betamethasone valerate cream for treating inflammatory skin diseases accompanied by bacterial infection and a preparation method thereof, belonging to the technical field of medicines. The composition is composed of active ingredients, an oil phase base, a consistency regulator, a moisturizer, an emulsifier, a stabilizer, a bacteriostat, and the rest of water. The cream has moderate viscosity, good drug stability, simple process, and suitable in industrial production.

The invention relates to the field of organic synthesis and medicinal chemistry, in particular to a kind of fusidic acid derivative with a novel structure and a synthesis method and application thereof. The optimized derivative comprises 3beta-[(2-amino) acetoxyl]-21-fusidate benzyl ester, 3beta-[(2-amino)propionyloxy]-21-fusidate benzyl ester, 3beta-[(2-amino-4-methyl)acetoxy]-21-fusidate benzylester, 3beta- (3-aminopropionyloxy)-21-fusidate benzyl ester, 3beta-(4-aminobutyryl acyloxy)-21-fusidate benzyl ester, 3beta-(8-aminocapryloyloxy)-21-fusidate benzyl ester, 3beta(11-aminohendecanoyl)-21-fusidate benzyl ester, and 3beta-(L-lysyl oxide)- 21-fusidate benzyl ester. The fusidic acid derivative of the invention has an anti-tumor effect and a clear action mechanism, and can be applied tothe development of a novel anti-tumor medicine.

The invention belongs to the technical field of medicinal chemical small molecule structure modified medicines, and discloses chemically modified fusidic acid, a preparation method thereof and an application of the chemically modified fusidic acid. The chemical structural formula of the chemically modified fusidic acid is as shown in the specification, and R is mono-substituted or poly-substitutedaromatic ring groups containing benzene rings and / or thiophene rings or furan rings. Fusidic acid serving as an extract of a natural product is structurally chemically modified to obtain the aromaticring group substituted chemically modified fusidic acid. The chemically modified fusidic acid can be applied to preparation of a medicinal preparation and antibacterial activity of bacteria, and is also applied to preparation of bacterial infection prevention, inhibition, control and / or treatment. In addition, the chemically modified fusidic acid can also be applied to the field of food or drinksafety and / or instrument disinfection.

The invention relates to the field of organic synthesis and pharmacochemistry, and in particular, relates to fusidic acid derivatives with a novel structure and a preparation method and an applicationthereof. Preferably, the derivatives comprise 3[beta]-[(2-amino)acetoxyl]-21-benzyl fusilate, 3[beta]-[(2-amino)propionyloxy]-21-benzyl fusilate, 3[beta]-[(2-amino-4-methyl)valeryloxy]-21-benzyl fusilate, 3[beta]-(3-aminopropionyloxy)-21-benzyl fusilate, 3[beta]-(4-aminobutyryloxy)-21-benzyl fusilate, 3[beta]-(8-aminocapryloyloxy)-21-benzyl fusilate, 3[beta]-(11-aminoundecanoyloxy)-21-benzyl fusilate, and 3[beta]-(L-lysyloxy)-21-benzyl fusilate; the fusidic acid derivatives are used for preparing antitumor drugs.

The invention discloses a method for extracting and purifying fusidic acid. The method comprises the following steps: S1) preparing dry mycelia: separating fusidic acid fermentation liquor, taking mycelia and drying, thereby acquiring dry mycelia; S2) preparing a concentrated solution using an organic solvent for soaking the dry mycelia acquired in the step S1), taking an organic solvent and concentrating, thereby acquiring the concentrated solution; S3) preparing fusidic acid: extracting, decolorizing, concentrating for crystallizing and drying the concentrated solution acquired in the step S2), thereby acquiring a crude product of fusidic acid; re-crystallizing and drying the crude product of fusidic acid, thereby acquiring fusidic acid. According to the invention, the dosage of organicsolvent and extraction agent can be greatly reduced and the cost for extracting and purifying fusidic acid can be lowered; the organic solvent and extraction agent can be recycled, so as to protect environment; the method disclosed by the invention is stable in process, simple and convenient in operation and suitable for industrial production.

The invention discloses a new purpose of yunnannmycin serving as biopesticide. The research result of the invention indicates that: the yunnannmycin has good effects for preventing and curing tomato virus disease caused by cucumber mosaic virus, common tobacco mosaic virus, tobacco potato virus X, tobacco potato virus Y and TEV, tomato virus disease caused by tobacco vein-distorting virus and virus disease, mosaic disease, fern leaf, little-leaf disease, spot disease, streak disease, malformation, dwarf virus disease, sickly yellow flower and putrescence, etc. of tomatos, capsicum and Chinese cabbages caused by cucumber mosaic virus and common tobacco mosaic virus, etc. The yunnannmycin is the biopesticide with good developing and applying prospects.